LXEO has 36-month beta value of 1.23. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LXEO is 25.04M, and currently, short sellers hold a 13.04% ratio of that float. The average trading volume of LXEO on May 12, 2025 was 888.48K shares.
LXEO) stock’s latest price update
The stock price of Lexeo Therapeutics Inc (NASDAQ: LXEO) has dropped by -10.33 compared to previous close of 3.00. Despite this, the company has seen a fall of -42.03% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-05 that Lexeo Therapeutics, Inc. established further positive interim data from phase 1/2 SUNRISE-FA study using LX2006 for the treatment of patients with Friedreich’s Ataxia Cardiomyopathy. Pivotal LXEO registration study of LX2006 for the treatment of patients with Friedreich’s Ataxia expected to start in 2026, with data release possible in 2027. The global Friedreich’s Ataxia market is projected to reach $3.49 billion by the end of 2034.
LXEO’s Market Performance
Lexeo Therapeutics Inc (LXEO) has seen a -42.03% fall in stock performance for the week, with a 13.98% gain in the past month and a -45.66% plunge in the past quarter. The volatility ratio for the week is 19.44%, and the volatility levels for the past 30 days are at 18.54% for LXEO. The simple moving average for the past 20 days is -18.22% for LXEO’s stock, with a -61.32% simple moving average for the past 200 days.
Analysts’ Opinion of LXEO
Many brokerage firms have already submitted their reports for LXEO stocks, with Robert W. Baird repeating the rating for LXEO by listing it as a “Outperform.” The predicted price for LXEO in the upcoming period, according to Robert W. Baird is $28 based on the research report published on June 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LXEO reach a price target of $22. The rating they have provided for LXEO stocks is “Buy” according to the report published on June 06th, 2024.
Stifel gave a rating of “Buy” to LXEO, setting the target price at $20 in the report published on November 28th of the previous year.
LXEO Trading at -12.57% from the 50-Day Moving Average
After a stumble in the market that brought LXEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.21% of loss for the given period.
Volatility was left at 18.54%, however, over the last 30 days, the volatility rate increased by 19.44%, as shares surge +23.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.03% lower at present.
During the last 5 trading sessions, LXEO fell by -42.03%, which changed the moving average for the period of 200-days by -77.15% in comparison to the 20-day moving average, which settled at $3.29. In addition, Lexeo Therapeutics Inc saw -59.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXEO starting from Townsend Richard Nolan, who sale 4,326 shares at the price of $4.41 back on Feb 19 ’25. After this action, Townsend Richard Nolan now owns 220,119 shares of Lexeo Therapeutics Inc, valued at $19,091 using the latest closing price.
See Tai Sandi, the Chief Development Officer of Lexeo Therapeutics Inc, sale 1,486 shares at $4.41 during a trade that took place back on Feb 19 ’25, which means that See Tai Sandi is holding 53,889 shares at $6,558 based on the most recent closing price.
Stock Fundamentals for LXEO
The total capital return value is set at -0.85. Equity return is now at value -85.37, with -67.10 for asset returns.
Based on Lexeo Therapeutics Inc (LXEO), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -8.18. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -772.01.
Currently, EBITDA for the company is -96.22 million with net debt to EBITDA at 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.52.
Conclusion
To put it simply, Lexeo Therapeutics Inc (LXEO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
